Active substance
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Bonteo 20 mcg per 80 mcl | 250 µ/ml | Solution for injection · Subcutaneous use | 1 Pre-filled pen | SAR 1155.35 | Biological · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Valid |
| FORTEO 20 MCG per 80MCL | 250 µ/ml | Solution for injection · Subcutaneous use | 1 Pre-filled pen | SAR 1421.95 | Biological · Prescription | ELI LILLY NEDERLAND B.V. | Valid |
| Sondelbay | 250 µg/ml | Solution for injection · Subcutaneous use | 1 Pre-filled pen | SAR 952.90 | Biological · Prescription | Boston Oncology Arabia | Valid |
| TERROSA | 250 µ/ml | Solution for injection · Subcutaneous use | 1 Cartridge | SAR 1003.05 | Biological · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
HYPOPARATHYROIDISM; OSTEOPOROSIS
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| FORTEO | 0.56MG/2.24ML (0.25MG/ML) | solution · subcutaneous | LILLY | Prescription | 26 Nov 2002 |
| BONSITY | 0.56MG/2.24ML (0.25MG/ML) | solution · subcutaneous | ALVOGEN | Prescription | 4 Oct 2019 |
| TERIPARATIDE | 0.56MG/2.24ML (0.25MG/ML) | solution · subcutaneous | TEVA PHARMS USA | Prescription | 16 Nov 2023 |
| TERIPARATIDE | 0.56MG/2.24ML (0.25MG/ML) | solution · subcutaneous | APOTEX | Prescription | 16 Nov 2023 |
| TERIPARATIDE | 0.56MG/2.24ML (0.25MG/ML) | solution · subcutaneous | ALMAJECT | Prescription | 4 Jun 2024 |
| TERIPARATIDE | 0.56MG/2.24ML (0.25MG/ML) | solution · subcutaneous | AMPHASTAR PHARMS INC | Prescription | 12 Dec 2025 |
| FORTEO | 0.75MG/3ML (0.25MG/ML) | solution · subcutaneous | LILLY | Discontinued | 26 Nov 2002 |
| PARATHAR | 200 UNITS/VIAL | injectable · injection | SANOFI AVENTIS US | Discontinued |
Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and nonvertebral fractures but not hip fractures has been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
Terrosa is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
Movymia is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
Livogiva is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
Sondelbay is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
Teriparatide SUN is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1).
Kauliv is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1).
Teriparatide is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
Treatment of osteoporosis
Treatment of osteoporosis
Treatment of osteoporosis
Qutavina is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-TERIPARATIDE INJECTION | 02498804 | 250 MCG / ML | SOLUTION · SUBCUTANEOUS | APOTEX INC |
| OSNUVO | 02495589 | 250 MCG / ML | SOLUTION · SUBCUTANEOUS | AVIR PHARMA INC. |
| TEVA-TERIPARATIDE INJECTION | 02486423 | 250 MCG / ML | SOLUTION · SUBCUTANEOUS | TEVA CANADA LIMITED |
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | BONSITY 560 MCG/2.24 ML PEN | $479.95105 | per ML | 23 Sep 2026 |
| US NADAC | FORTEO 560 MCG/2.24 ML PEN INJ | $1841.27488 | per ML | 23 Sep 2026 |
| US NADAC | TERIPARATIDE 560 MCG/2.24 ML PEN | $479.95105 | per ML | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.